Misyo (Methadone Hydrochloride)

Methadone is a full agonist at the mu‑opioid receptor. By binding strongly and persistently, it maintains steady opioid receptor activation, which suppresses withdrawal, diminishes cravings, and produces analgesia. Its long half‑life ensures stable plasma concentrations, reducing the peaks and troughs seen with shorter‑acting opioids.

The dose of Misyo is individualized by the prescribing clinician based on the patient’s opioid use history, pain severity, metabolic status, and response to therapy. No fixed regimen is provided here; the prescriber sets the appropriate dose and titration schedule.

Data on methadone use in pregnancy and lactation are limited. It may be used when the benefit to the mother outweighs potential risks to the fetus or infant, but careful monitoring is required. Breastfeeding while on methadone is possible under medical supervision, with attention to infant sedation and respiratory status.

To order Misyo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both methadone (Misyo) and buprenorphine are used for opioid dependence, but methadone is a full mu‑opioid agonist with a longer half‑life, offering more potent analgesia. Buprenorphine is a partial agonist, generally associated with a lower risk of respiratory depression but may be less effective for severe pain. Choice depends on patient history, treatment goals, and safety considerations.

Misyo should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect from moisture and heat. Keep the product out of reach of children and avoid exposure to direct sunlight or extreme humidity.

Misyo is administered orally, typically as a tablet or liquid formulation, as directed by the prescriber. It should be taken with or without food according to the dosing instructions provided, and the patient should not crush or chew extended‑release forms unless specifically advised.

The most serious risks include respiratory depression, which can be fatal if not recognized promptly, and cardiac complications such as QT interval prolongation leading to arrhythmias. Seizures and severe hypotension are also rare but critical adverse events that require immediate medical attention.

Misyo is contraindicated in patients with known hypersensitivity to methadone, those with significant uncontrolled cardiac arrhythmias, severe respiratory insufficiency, or acute severe asthma. Caution is also advised for individuals taking other CNS depressants, MAO inhibitors, or drugs that markedly prolong the QT interval.